Exhausted But Can't Sleep? It's Probably Your Cortisol

If you fall into bed exhausted and then lie there, mind racing and body tense, you are not imagining it — and it is not a sleep problem in the conventional sense. The most likely explanation is elevated cortisol at a time when it should be almost undetectable. Cortisol is the body's primary stress hormone, designed to peak in the morning and decline steadily through the day. In people under chronic stress, that decline fails to happen. Instead, cortisol stays elevated into the evening, signals the brain to remain alert, and makes restful sleep physiologically difficult. This pattern is called hyperarousal, and it is now the most widely supported mechanistic explanation for stress-related insomnia. Understanding it — and what the evidence says about addressing it — is the starting point for actually fixing this kind of sleep problem.

What does "wired but tired" actually mean?

The phrase describes a physiological paradox that millions of people recognise. The body is genuinely fatigued: muscles are depleted, reaction times are slow, and concentration has collapsed. But the nervous system remains in a state of activation. Heart rate is slightly elevated, thoughts cycle rapidly, and the prospect of sleep feels remote despite the exhaustion.

From a pharmacological perspective, this is not a contradiction. Fatigue and alertness are regulated by separate systems. Fatigue accumulates via adenosine — a chemical byproduct of neurological activity that builds pressure for sleep throughout the day. Alertness, by contrast, is driven in large part by the hypothalamic-pituitary-adrenal (HPA) axis and its end product, cortisol. These two systems can pull in opposite directions simultaneously: adenosine says sleep, cortisol says stay vigilant.

When cortisol wins at night, sleep is disrupted even when the need for it is acute.

Why does cortisol spike — or stay elevated — at night?

Cortisol follows a diurnal rhythm under normal conditions: it surges sharply in the hour after waking (a normal response called the cortisol awakening response), then declines through the day, reaching near-zero levels around midnight. This decline is partly regulated by the sleep process itself — deep sleep actively suppresses HPA axis output, and the two systems exist in a reciprocal relationship.

Chronic stress disrupts this rhythm in two ways. First, it chronically upregulates the HPA axis, producing higher average cortisol output across the day. Second, it blunts the feedback mechanisms that normally switch cortisol production off. The result is that by late evening — when cortisol should be at its lowest — levels remain biologically significant.

A 2022 systematic review and meta-analysis published in Sleep Medicine Reviews, involving 20 case-control studies with 449 patients with chronic insomnia and 357 good-sleeping controls, found that insomnia is associated with a state of 24-hour HPA axis hyperactivity, with measurably elevated cortisol and ACTH secretion compared to healthy sleepers.[1] The authors concluded that this hyperarousal is not merely a consequence of poor sleep but a central driver of it — a finding that aligns with the broader clinical consensus on stress-driven insomnia.

What happens in the brain when cortisol is elevated at bedtime?

Cortisol crosses the blood-brain barrier and acts directly on glucocorticoid receptors distributed throughout the limbic system, prefrontal cortex, and hypothalamus. At physiologically elevated nighttime levels, it promotes the release of corticotropin-releasing hormone (CRH) from the hypothalamus, which in turn stimulates further ACTH and cortisol production. This self-reinforcing loop is one reason why stress-related sleep disruption can become persistent — the biological conditions that prevent sleep also maintain the neurological state that created them.

Elevated CRH signalling at night also suppresses slow-wave (deep) sleep specifically. This is the sleep stage most critical for physical recovery, memory consolidation, and metabolic regulation. So even when someone with elevated evening cortisol does fall asleep, the architecture of that sleep is compromised. They may sleep for seven or eight hours but wake feeling unrestored — another hallmark of HPA-driven insomnia that standard sleep hygiene advice fails to address.

Does ashwagandha have evidence for reducing evening cortisol?

Ashwagandha (Withania somnifera) is among the most studied adaptogens for HPA axis modulation, and the evidence base is now substantial enough to draw conclusions with reasonable confidence.

The active compounds responsible for most of its adaptogenic effects are withanolides — steroidal lactones that interact directly with glucocorticoid receptors in the brain. This is not a vague "stress support" claim: the mechanism involves modulating CRH signalling at the hypothalamic level, which reduces the downstream cascade of ACTH and cortisol secretion. It is the same axis implicated in stress-driven insomnia, targeted at the source.

Clinically, a well-cited randomised controlled trial by Lopresti et al. (2019), conducted in 60 adults with chronic stress, found that 300 mg of standardised ashwagandha root extract taken twice daily for 60 days produced a 27.9% reduction in serum cortisol compared to a 7.9% reduction in the placebo group.[2] A more recent 2025 systematic review and meta-analysis published in Nutrition & Health, pooling seven controlled trials with 488 participants, confirmed statistically significant reductions in serum cortisol across studies using ashwagandha supplementation.[3]

Importantly, effects on cortisol appear to be time-dependent. Most trials report meaningful changes at eight weeks of consistent supplementation, with some showing earlier effects. Ashwagandha is not a fast-acting sedative — it modulates the underlying hormonal environment, which takes time to shift. Early-stage evidence suggests sleep outcomes follow the cortisol reduction, typically improving most noticeably after four to six weeks of supplementation.

How does magnesium support the shift from stress to sleep?

Magnesium plays a distinct but complementary role in the stress-sleep interface. It acts as a natural antagonist at NMDA receptors — glutamate-gated ion channels that, when overactive, promote neurological excitation and maintain the alert state. By limiting NMDA activity, magnesium helps tilt the balance of neurological tone toward the inhibitory, parasympathetic side.

Magnesium also modulates the HPA axis directly: deficiency states are associated with exaggerated cortisol responses to stress, and supplementation in deficient individuals has been shown to reduce cortisol reactivity. Chronic stress accelerates urinary magnesium excretion, creating a physiological loop in which stress depletes the mineral whose presence would help buffer further stress responses.

The chelated form — magnesium bisglycinate — is particularly relevant here because it combines magnesium with glycine, an inhibitory neurotransmitter in its own right. A 2025 randomised, double-blind, placebo-controlled trial found that four weeks of magnesium bisglycinate supplementation (250 mg elemental magnesium combined with 1,523 mg glycine daily) produced a statistically significant reduction in Insomnia Severity Index scores compared to placebo, with the compound well tolerated and side effects less frequent in the active group than in the placebo arm.[4]

Does apigenin contribute to this picture?

Apigenin is a flavonoid compound with established activity at GABA-A receptors — the primary inhibitory receptors in the central nervous system. It acts as a positive allosteric modulator at the benzodiazepine-binding site on GABA-A, enhancing the chloride ion influx that calms neuronal firing. In the context of cortisol-driven hyperarousal, apigenin addresses the downstream neurological consequence: excessive excitatory tone.

A 2024 review in Frontiers in Nutrition synthesised the current evidence and described apigenin's GABAergic activity as well-characterised at the preclinical level, with early human observational data suggesting a positive correlation between dietary apigenin intake and sleep quality in large cohort studies.[5] Formal human RCT evidence on isolated apigenin at supplement doses is an acknowledged gap in the literature — a limitation worth stating clearly. What is well established is the mechanism by which it acts, and the plausibility of its role in combination with compounds targeting cortisol higher up the signalling chain.

How ARC addresses the cortisol-sleep connection

ARC was formulated around this specific pattern. Every ingredient maps directly to the physiological sequence described here: ashwagandha's withanolides modulate HPA axis output at the hypothalamic level; magnesium bisglycinate supports parasympathetic tone and buffers cortisol reactivity; apigenin engages GABA-A receptors to reduce the neurological hyperarousal that elevated cortisol produces; and L-theanine promotes alpha-wave brain activity — the signature of relaxed, non-anxious wakefulness that precedes natural sleep onset. ARC contains no melatonin, which is intentional. Melatonin does not address cortisol. It signals light-dark status to the pineal gland — a separate system entirely. For sleep problems rooted in stress and hyperarousal, it addresses a different question than the one the body is asking.

FAQ

Why am I so tired but can't sleep at night? The most common explanation is elevated cortisol from chronic stress. Cortisol is a stimulating hormone that should be near zero by bedtime, but in people under sustained pressure it remains biologically active, keeping the nervous system in a state of alert even when the body is physically exhausted. This pattern is called hyperarousal and is well-documented in clinical sleep research as a primary driver of stress-related insomnia.

Can lowering cortisol actually improve sleep quality? The evidence suggests it can, particularly for those whose sleep problems are driven by stress rather than other causes. Multiple randomised controlled trials have found that ashwagandha supplementation significantly reduces serum cortisol and simultaneously improves sleep quality scores, with effects most pronounced at eight weeks of supplementation. Magnesium supplementation has also shown significant reductions in insomnia severity in controlled trials.

How long does it take for cortisol-lowering supplements to improve sleep? Adaptogens such as ashwagandha typically show measurable effects on cortisol at four to eight weeks of consistent use. This is not a sedative effect — it represents a gradual recalibration of the HPA axis. Magnesium and apigenin may act more quickly given their more direct neurological mechanisms, but individual responses vary and are influenced by baseline stress levels, diet, and sleep environment.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making changes to your supplement routine.

Food supplements should not be used as a substitute for a varied and balanced diet.

Written by Cameron Webb, MPharm, PhD 

References

1. Vargas I, Vgontzas AN, Abelson JL, et al. HPA axis activity in patients with chronic insomnia: A systematic review and meta-analysis of case-control studies. Sleep Med Rev. 2022;62:101589. 
2. Lopresti AL, Smith SJ, Malvi H, Kodgule R. An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: A randomized, double-blind, placebo-controlled study. Medicine (Baltimore). 
3. Albalawi AA, Hakami AY, Hakami MA, et al. Dual impact of Ashwagandha: Significant cortisol reduction but no effects on perceived stress — A systematic review and meta-analysis. Nutr Health. 2025. 
4. Magnesium Bisglycinate Supplementation in Healthy Adults Reporting Poor Sleep: A Randomized, Placebo-Controlled Trial. Nat Sci Sleep. 2025. 
5. Zhao M, Tuo H, Wang S, Zhao L. Apigenin: a natural molecule at the intersection of sleep and aging. Front Nutr. 2024;11:1359176. 
6. Nielsen FH. Magnesium deficiency and increased inflammation: current perspectives. J Inflamm Res. 2018;11:25-34.